Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $3.4M | $0 | $1.3M | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $3.4M | $0 | $0 | $0 |
| Gross margin | 100.0% | — | 0.0% | — |
| R&D | $8.0M | $0 | $30.3M | $34.4M |
| Operating income | −$8.7M | $0 | −$42.9M | −$49.0M |
| EBITDA | −$8.2M | $0 | $4.8M | $3.1M |
| Net income | −$9.0M | $0 | −$34.1M | $13.3M |
| Net margin | -261.1% | — | -2579.0% | — |
| EPS (diluted) | -0.21 | 0.00 | -3.68 | -0.79 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds BCYP.
No tracked institution reports a position in BCYP as of their last filing.
| Execution date | Ratio |
|---|---|
| 2015-07-02 | 1-for-50reverse |
No one on the platform has traded BCYP yet.
| $449M |
| — |
| IVVDInvivyd, Inc. | $0.94 | +5.83% | $278M | — |
| ORTXOrchard Therapeutics plc | $16.70 | +0.30% | $380M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.